University of Prince Edward Island

Other

Nono Inc.

H:s Rigshospitalet

Tracy Doucette

Michael Tymianski

Peter S Lu

Michael P Belmares

Kenneth A Mendoza

David Garman

Melissa Perry

Catherine Ryan

R Andrew Tasker

Henriette Husum Bak-Jensen

Andrew Tasker

Kenneth Mendoza

The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.

Treatment for anxiety

Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the animal in the second postnatal week, wherein after treatment with the kainate receptor agonist the animal exhibits reproducible seizure-like symptoms when exposed to mild to moderate stressors. Rats treated using the above method are particularly useful as a non-human system for studying temporal lobe epilepsy, as well as for studying the efficacy of potential anti-epileptic compounds and pharmaceutical preparations.

Developmental animal model of temporal lobe epilepsy

Growing community of inventors

Stanhope, Canada

Tracy Doucette